HUMAN MONOCLONAL ANTIBODY WITH SPECIFICITY FOR DENGUE VIRUS SEROTYPE 1 E PROTEIN AND USES THEREOF

• Main Authors: NG MAH LEE MARY, LOK SHEE MEI, MACARY PAUL ANTHONY, BRENDON JOHN HANSON, PETRA EVELIINA KUKKARO, EN WE TEO, LIM ANGELINE PEI CHIEW, EE PING EVELYN TEOH
• Format: Patent
• Language: English; Japanese
• Published: 29.03.2018
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

PROBLEM TO BE SOLVED: To provide compositions and methods for the treatment or prevention of dengue virus infection in a vertebrate subject.SOLUTION: Human neutralizing monoclonal antibodies disclosed herein are isolated from EBV immortalized B cells derived from patients who have recovered from dengue infection, and bind to a dengue virus serotype 1 envelope protein or a fragment thereof. Also provided are methods for administering such antibodies to a vertebrate subject in an amount effective to reduce, eliminate or prevent relapse from infection.SELECTED DRAWING: Figure 1 【課題】脊椎動物対象におけるデングウイルス感染を治療または予防するための組成物および方法を提供する。【解決手段】デング感染から回復した患者に由来するEBV不死化B細胞から単離された、デングウイルス血清型1のエンベロープタンパク質またはその断片に結合する、ヒト中和モノクローナル抗体を開示する。そのような抗体を、感染からの再発を抑制する、排除する、または防止するのに有効な量で脊椎動物対象に投与するための方法を提供する。【選択図】図１